Form 4: Catalyst Pharmaceuticals CEO Richard Daly Exercises Options and Sells Shares

Richard Daly, CEO of Catalyst Pharmaceuticals, exercised stock options and sold a portion of the acquired shares on June 4, 2024.

Summary

• On June 4, 2024, Richard J. Daly, the President and CEO of Catalyst Pharmaceuticals, exercised options to purchase 40,000 shares of common stock at a price of $4.01 per share.
• Following the exercise, Daly sold 17,323 shares on the open market at a price of $15.975 per share to cover the exercise price and associated tax withholding.
• After these transactions, Daly directly owns 234,824 shares of Catalyst Pharmaceuticals common stock and 1,731,012 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard Form 4 filing detailing insider transactions. The transactions themselves don't necessarily indicate a positive or negative outlook.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is likely insignificant given the context of exercising options and covering tax obligations.

Key Dates